Memgen LLC is a biotechnology company based in Dallas, TX, specializing in viral cancer immunotherapy. Their lead immunotherapy, MEM-288, combines a proprietary CD40 ligand with interferon beta to generate a robust, tumor-targeted T cell immune response. In clinical trials, MEM-288 has shown promising results in advanced non-small cell lung cancer patients, with tumor shrinkage and disease control observed in 50% of participants.
With a management team and board of directors boasting extensive experience in the biotechnology, pharmaceutical, and finance sectors, Memgen is well-positioned to advance their innovative cancer immunotherapies. Their scientific advisory board, which includes renowned experts in the field of immunotherapy, provides valuable guidance in the development of their treatments. Memgen's mission is to harness the power of the immune system to combat cancer and improve patient outcomes.
Generated from the website